Literature DB >> 8314308

Effects of nIFN beta and rIFN gamma on growth and morphology of two human melanoma cell lines: comparison between two- and three-dimensional culture.

A Görlach1, P Herter, H Hentschel, P J Frosch, H Acker.   

Abstract

We compared the anti-proliferative effects of natural interferon beta (nIFN beta) and recombinant interferon gamma (rIFN gamma) on 2 human melanoma cell lines, IGRI and SK-Mel28, grown in 2-dimensional monolayer and in 3-dimensional spheroid culture. In monolayer culture, growth of both lines was inhibited in a dose-dependent manner by 5-day treatments with IFN in concentrations ranging between 1 and 5,000 IU/ml. Incubations with 120 IU/ml nIFN beta or 25 IU/ml rIFN gamma led to a 50% growth inhibition of IGRI cells. A 50% growth inhibition of SK-Me128 cells was obtained with 60 IU/ml nIFN beta, whereas even 5,000 IU/ml rIFN gamma inhibited the growth of this line by only 30%. Growing these melanoma cell lines in 3-dimensional spheroid culture for 5 days reduced their sensitivity to interferon. Growth inhibition values of 50% were achieved with 3,000 IU/ml rIFN gamma or 9,000 IU/ml nIFN beta for IGRI spheroids and 10,000 IU/ml nIFN beta for SK-Me128 spheroids, while 10,000 IU/ml rIFN gamma reduced the growth of SK-Me128 spheroids by only 25%. Outgrowth tests showed that the proliferative capacity after 5-day incubations with IFN was only reduced in IGRI spheroids treated with high doses of nIFN beta. The macroscopically observed increased density of interferon-treated spheroids could be confirmed by light microscopy as corresponding to reduced intercellular space in these spheroids. Scanning electron microscopy furthermore showed variations on the surface of IFN-treated spheroids as well as in cellular organization and structures between cells, hinting at a possible involvement of extracellular matrix substances in the reaction to interferons.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8314308     DOI: 10.1002/ijc.2910560218

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab.

Authors:  Ines Beyer; Zongyi Li; Jonas Persson; Ying Liu; Ruan van Rensburg; Roma Yumul; Xiao-Bing Zhang; Mien-Chie Hung; André Lieber
Journal:  Mol Ther       Date:  2010-11-16       Impact factor: 11.454

Review 2.  Anti-Cancer Drug Validation: the Contribution of Tissue Engineered Models.

Authors:  Mariana R Carvalho; Daniela Lima; Rui L Reis; Joaquim M Oliveira; Vitor M Correlo
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

3.  The microenvironment determines the breast cancer cells' phenotype: organization of MCF7 cells in 3D cultures.

Authors:  Silva Krause; Maricel V Maffini; Ana M Soto; Carlos Sonnenschein
Journal:  BMC Cancer       Date:  2010-06-07       Impact factor: 4.430

4.  3D porous chitosan-alginate scaffolds: a new matrix for studying prostate cancer cell-lymphocyte interactions in vitro.

Authors:  Stephen J Florczyk; Gang Liu; Forrest M Kievit; Allison M Lewis; Jennifer D Wu; Miqin Zhang
Journal:  Adv Healthc Mater       Date:  2012-07-06       Impact factor: 9.933

Review 5.  Engineered in vitro tumor models for cell-based immunotherapy.

Authors:  Yuta Ando; Chelsea Mariano; Keyue Shen
Journal:  Acta Biomater       Date:  2021-04-20       Impact factor: 10.633

6.  Peptide hydrogelation and cell encapsulation for 3D culture of MCF-7 breast cancer cells.

Authors:  Hongzhou Huang; Ying Ding; Xiuzhi S Sun; Thu A Nguyen
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

7.  Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes.

Authors:  C Feder-Mengus; S Ghosh; W P Weber; S Wyler; P Zajac; L Terracciano; D Oertli; M Heberer; I Martin; G C Spagnoli; A Reschner
Journal:  Br J Cancer       Date:  2007-03-06       Impact factor: 7.640

8.  Strategies to increase drug penetration in solid tumors.

Authors:  Il-Kyu Choi; Robert Strauss; Maximilian Richter; Chae-Ok Yun; André Lieber
Journal:  Front Oncol       Date:  2013-07-26       Impact factor: 6.244

9.  Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model.

Authors:  Sharon Wei Ling Lee; Giulia Adriani; Erica Ceccarello; Andrea Pavesi; Anthony Tanoto Tan; Antonio Bertoletti; Roger Dale Kamm; Siew Cheng Wong
Journal:  Front Immunol       Date:  2018-03-06       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.